A unanimous approval, a trial failure, sort of, a cash raise with bad timing, and a general biotech selloff. Let's go over the stories we've been watching, commenting on and trading this week.
Exact Sciences (NASDAQ:EXAS)
Exact Sciences received a unanimous recommendation from the molecular and clinical genetics panel of the FDA's Medical Device Advisory Committee. Read more here.
Insmed Incorporated (NASDAQ:INSM)
Insmed missed the primary endpoint in their phase 2 trial of ARIKACE but hit statistical significance on a much more important secondary endpoint. Read the article for details.
Endocyte (NASDAQ:ECYT)
Endocyte Raised $94.5 million via a secondary offering. ECYT stock sold off losing 17% of its value from the time the offering was announced until the offering priced. Read the article to find out what's next for ECYT.
iShares Biotechnology ETF (NASDAQ:IBB)
The biotech market has been selling off since highs in late February. Read the article to find out where key support levels are for the IBB.
Add new comment